{"title":"新型抗癫痫Kv7.2/7.3活化剂5,7-二甲基苯并[d]噻唑的设计、合成及构效关系","authors":"Denggao Zhang, Wei Xiang, Jie Liu, Wei Li, Zhen Qiao, KeWei Wang, Liming Shao","doi":"10.1016/j.ejmech.2025.117660","DOIUrl":null,"url":null,"abstract":"The activation of neuronal Kv7 channels has emerged as an important therapeutic strategy for epilepsy due to their role in regulating neuronal excitability. Retigabine (RTG), a Kv7.2/7.3 channel activator, was previously approved for epilepsy treatment but was withdrawn in 2017 its side effects of ophthalmological and dermatological pigmentation. Despite this setback, Kv7.2/7.3 channel remains a promising target for the development of antiepileptic drugs (AEDs). Previous studies have attributed the toxic metabolic quinone/azaquinone diimines and associated blue discoloration of RTG to its electron-rich tri-amine aromatic scaffold. A common strategy to mitigate this toxicity involves removing the <em>ortho-</em>aniline moiety of RTG. In this study, we designed and synthesized a series of compounds based on dimethylbenzene heterocyclic scaffolds as Kv7.2/7.3 activators. Among them, compound <strong>2c</strong> demonstrated improved efficacy in Rb<sup>+</sup> efflux assays and exhibited comparable activity in whole-cell patch clamp recordings on Kv7.2/7.3 channels. Moreover, compound <strong>2c</strong> was effective in both maximal electroshock seizure (MES) and subcutaneous pentylenetetrazol (<em>sc-</em>PTZ) mouse models, with ED<sub>50</sub> values of 4.02 mg/kg and 43.17 mg/kg, respectively. The LD<sub>50</sub> value of <strong>2c</strong> in acute toxicity experiments was 340.35 mg/kg (95% CI: 293.68–394.45) in mice. Additionally, <strong>2c</strong> exhibited locomotor impairment with at TD<sub>50</sub> of 48.93 mg/kg in an open field test and 49.25 mg/kg in a rotarod test. Compound <strong>2c</strong> also demonstrated reasonable pharmacokinetic (PK) properties and blood-brain barrier (BBB) penetration, along with good photostability. Site-directed mutagenesis, combined with molecular docking, confirmed that <strong>2c</strong> interacted with key residues (W236, F305, and L299) in the Kv7.2 channel. Our findings suggest that compound <strong>2c</strong> is a promising lead compound with a novel scaffold as a Kv7.2/7.3 activator for the management of epilepsy.","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"219 1","pages":""},"PeriodicalIF":6.0000,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Design, synthesis, and structure-activity relationship of 5,7- dimethylbenzo[d]thiazoles as novel Kv7.2/7.3 activators with antiepileptic effects\",\"authors\":\"Denggao Zhang, Wei Xiang, Jie Liu, Wei Li, Zhen Qiao, KeWei Wang, Liming Shao\",\"doi\":\"10.1016/j.ejmech.2025.117660\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The activation of neuronal Kv7 channels has emerged as an important therapeutic strategy for epilepsy due to their role in regulating neuronal excitability. Retigabine (RTG), a Kv7.2/7.3 channel activator, was previously approved for epilepsy treatment but was withdrawn in 2017 its side effects of ophthalmological and dermatological pigmentation. Despite this setback, Kv7.2/7.3 channel remains a promising target for the development of antiepileptic drugs (AEDs). Previous studies have attributed the toxic metabolic quinone/azaquinone diimines and associated blue discoloration of RTG to its electron-rich tri-amine aromatic scaffold. A common strategy to mitigate this toxicity involves removing the <em>ortho-</em>aniline moiety of RTG. In this study, we designed and synthesized a series of compounds based on dimethylbenzene heterocyclic scaffolds as Kv7.2/7.3 activators. Among them, compound <strong>2c</strong> demonstrated improved efficacy in Rb<sup>+</sup> efflux assays and exhibited comparable activity in whole-cell patch clamp recordings on Kv7.2/7.3 channels. Moreover, compound <strong>2c</strong> was effective in both maximal electroshock seizure (MES) and subcutaneous pentylenetetrazol (<em>sc-</em>PTZ) mouse models, with ED<sub>50</sub> values of 4.02 mg/kg and 43.17 mg/kg, respectively. The LD<sub>50</sub> value of <strong>2c</strong> in acute toxicity experiments was 340.35 mg/kg (95% CI: 293.68–394.45) in mice. Additionally, <strong>2c</strong> exhibited locomotor impairment with at TD<sub>50</sub> of 48.93 mg/kg in an open field test and 49.25 mg/kg in a rotarod test. Compound <strong>2c</strong> also demonstrated reasonable pharmacokinetic (PK) properties and blood-brain barrier (BBB) penetration, along with good photostability. Site-directed mutagenesis, combined with molecular docking, confirmed that <strong>2c</strong> interacted with key residues (W236, F305, and L299) in the Kv7.2 channel. Our findings suggest that compound <strong>2c</strong> is a promising lead compound with a novel scaffold as a Kv7.2/7.3 activator for the management of epilepsy.\",\"PeriodicalId\":314,\"journal\":{\"name\":\"European Journal of Medicinal Chemistry\",\"volume\":\"219 1\",\"pages\":\"\"},\"PeriodicalIF\":6.0000,\"publicationDate\":\"2025-04-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Medicinal Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ejmech.2025.117660\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ejmech.2025.117660","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Design, synthesis, and structure-activity relationship of 5,7- dimethylbenzo[d]thiazoles as novel Kv7.2/7.3 activators with antiepileptic effects
The activation of neuronal Kv7 channels has emerged as an important therapeutic strategy for epilepsy due to their role in regulating neuronal excitability. Retigabine (RTG), a Kv7.2/7.3 channel activator, was previously approved for epilepsy treatment but was withdrawn in 2017 its side effects of ophthalmological and dermatological pigmentation. Despite this setback, Kv7.2/7.3 channel remains a promising target for the development of antiepileptic drugs (AEDs). Previous studies have attributed the toxic metabolic quinone/azaquinone diimines and associated blue discoloration of RTG to its electron-rich tri-amine aromatic scaffold. A common strategy to mitigate this toxicity involves removing the ortho-aniline moiety of RTG. In this study, we designed and synthesized a series of compounds based on dimethylbenzene heterocyclic scaffolds as Kv7.2/7.3 activators. Among them, compound 2c demonstrated improved efficacy in Rb+ efflux assays and exhibited comparable activity in whole-cell patch clamp recordings on Kv7.2/7.3 channels. Moreover, compound 2c was effective in both maximal electroshock seizure (MES) and subcutaneous pentylenetetrazol (sc-PTZ) mouse models, with ED50 values of 4.02 mg/kg and 43.17 mg/kg, respectively. The LD50 value of 2c in acute toxicity experiments was 340.35 mg/kg (95% CI: 293.68–394.45) in mice. Additionally, 2c exhibited locomotor impairment with at TD50 of 48.93 mg/kg in an open field test and 49.25 mg/kg in a rotarod test. Compound 2c also demonstrated reasonable pharmacokinetic (PK) properties and blood-brain barrier (BBB) penetration, along with good photostability. Site-directed mutagenesis, combined with molecular docking, confirmed that 2c interacted with key residues (W236, F305, and L299) in the Kv7.2 channel. Our findings suggest that compound 2c is a promising lead compound with a novel scaffold as a Kv7.2/7.3 activator for the management of epilepsy.
期刊介绍:
The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcomes critical review papers.
A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present the rational for a study, provide insight into the design of compounds or understanding of mechanism, or clarify the targets.